anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an application of currant anthocyanin in preparation of a medicine for inducing apoptosis of colon cancer cells. The anti-intestinal cancer medicine is prepared by taking the currant anthocyanin as a raw material and singly using or combining with other medicines capable of inducing the apoptosis of colon cancer cells. The medicine is in the form of oral liquid, tablet, capsule, granule, injection, ointment, or gel. The preparation method of the currant anthocyanin comprises the following steps: putting the currant fruit into anthocyanin extracting solution for extraction to obtain ethanol extract, purifying the currant extract by a macroporous adsorption resin chromatography cabinet, eluting the ethanol, performing rotary evaporation, concentrating, and performing vacuum freeze drying to obtain the currant anthocyanin. The currant anthocyanin can inhibit Caco-2 cell activity, has cytotoxicity, and can reduce proliferation rate. Resulting in apoptosis of Caco-2 cells. Therefore, the gooseberry anthocyanin can be proved to have the effect of inhibiting the colon cancer, and can be used for developing the medicine for preventing and treating the colon cancer according to the national standard.
Lower cross syndrome is common, with up to 85% of low back pain cases due to long-term postural faults (Lower crossed syndrome) and it has a negative result on our society. Global Postural Re-education (GPR) is an intervention that is used frequently for chronic low pain to improve pain and function. 50 low back pain patients with lower cross syndrome will be assigned randomly into 2 groups, Group A will receive a Global Postural Re-education approach and consists of 15 treatment sessions of Global Postural Re-education approach, performed 2times/week for 1 hour including patient education. Each treatment is individualized for every patient and for his/her pain-related limitation. Each session includes only 2-3 postures to increase the standardization of treatment. Group B will receive the conventional treatment in form of exercise program of (abdominal and pelvic floor strengthening) and (stretching exercise of back and hip flexor muscles) to improve pain and function in chronic low back pain patients
PROBLEM TO BE SOLVED: To provide a system capable of rapidly and conveniently preparing blood plasma without the risk of the cross infection with any immunological disease and also without the need of any device. SOLUTION: This system for preparing autologous plasma comprises a single use filter unit 16 having two inlets in fluid communication with each other, an outlet, and a filtration membrane selectively permeable to blood plasma separating the inlets from the outlet. Manually operable, single use pumps, pref. syringes 18 are connected to the inlets. A flow path is defined along the membrane between the pumps, whereby, whole blood can be repeatedly exchanged between the two pumps, past the membrane, to cause plasma to flow across the membrane and out of the outlet. A syringe can collect plasma from the outlet. Plasma thus collected can be simultaneously applied with a thrombin solution to a site on the body, thereby, forming a fibrin gel.
The present invention relates to a pharmaceutical complex preparation comprising clopidogrel and aspirin. In the complex preparation, granules having a clopidogrel layer coated with a fast-release protecting layer and asprin granules having an aspirin layer coated with an enteric coating layer are encapsulated. According to the present invention, a physical contact between clopidogrel and aspirin is interrupted to prevent an eutectic phenomenon fundamentally. Thus, it is possible to prevent a change in the contents, dissolution characteristics and bio-equivalence of the preparation in the short run, and to improve the stability of the preparation in the long run. It is also possible to prevent a damage of the stomach wall by coating aspirin with an enteric coating layer. In addition, a moisture-proof layer is used to improve the stability of water-sensitive clopidogrel and a salt thereof to minimize production of clopidogrel impurities without any change in dissolution amount of clopidogrel. Further, it is possible to reduce the amount of residual solvent contained in clopidogrel significantly with no need for an additional process, such as drying, and thus to reduce the production cost by virtue of a simple process.
Previous studies have shown, that when patients learn a new motor movement, it may cause a change in the way the nerves act in the area of the brain that controls movement. This change is called use-dependent plasticity. The ability of that part of the brain, called the motor cortex (M1), to reorganize plays a major role in the recovery of motor deficits post-stroke; hence the importance for further development of rehabilitative strategies that utilize this potential for recovery. In this proposed study, investigators will further examine influences of use-dependent plasticity in the non-injured M1 of healthy subjects and injured M1 of stroke subjects using a combination of non-invasive cortical stimulation, medication, and exercise techniques. In Aim 1, investigators will test the effect of drugs that interact specifically with different neurotransmitter systems on use-dependent plasticity in intact M1 of healthy humans. In Aim 2, investigators will identify the parameters for non-invasive transcranial magnetic stimulation (TMS) of M1 that are most effective to enhance use-dependent plasticity in intact healthy human M1. In Aim 3, investigators will test the drugs and rTMS protocols that were demonstrated to be most effective to enhance use- dependent plasticity in the Specific Aim 1 and 2 and apply them to participants who have experienced a stroke. Results from this study will help to inform future research about the efficacy of plasticity enhancing methods in injured M1 of stroke patients.
PURPOSE: To compare the effects of end-range manual therapy versus other conservative intervention on pain intensity, shoulder range of movement (ROM), and physical function in adhesive capsulitis (AC).
METHODS: Two reviewers conducted a comprehensive search from inception to December 2022. PUBMED, Cochrane Library, CINAHL, EMBASE, and PEDro databases were searched. Clinical trials investigating the effects of end-range mobilisation techniques on pain, ROM, and physical function in patients with AC were included. Methodological quality was evaluated using the PEDro scale, and bias risk was assessed using the Cochrane Collaboration tool. GRADE was used to assess the certainty of the evidence. Data were presented using forest plots, and the random effects models were applied according to the Cochrane handbook.
RESULTS: Ten randomised controlled trials were reviewed, involving 424 AC patients aged 20-70 years. Methodological quality of studies ranged from high to low. The end-range mobilisation showed improvements in pain intensity, shoulder abduction, internal rotation, and external rotation, and physical function compared to other conservative interventions in the short-and medium-terms. Certainty of the evidence was downgraded to very low.
CONCLUSIONS: Very low certainty evidence suggests that end-range mobilisation techniques improve pain intensity, shoulder ROM, and physical function in the short-and medium-term in AC.
Participants will receive single intramuscular injection of placebo as sterile 0.9 percent (%) saline for injection during Day -90 to Day -28. On Day 0, intranasal challenge with RSV-A Memphis 37b virus will occur for all participants.
Individuals will receive daily text messages with the goal of increasing daily walking by 2,000 more steps 5 days per week. Participants will be enrolled for a baseline period lasting 2 weeks where their average daily activity level will be assessed using a Fitbit device to generate an average daily step counts. Following completion of baseline, participants will be asked to generate a walking plan with the goal of walking an additional 2,000 steps above their baseline activity level on 5 days per week. This walking plan will include details about day of the week, time of day, and location of walking. Once participants have completed their walking plan, they will receive daily texts based on the 5 identified BCTs for the duration of the 10-week intervention. All BCTs will be delivered daily. The goal of the text messages will be to encourage habit formation for walking behavior.
Excess adipose tissue, as well as its distribution, correlates strongly with disorders of lipid and liver parameters and chronic inflammation. The pathophysiology of metabolic diseases caused by obesity is associated with the dysfunction of visceral adipose tissue. Effective and alternative interventions such as the Bioenteric Intragastric Balloon and bariatric surgeries such as the Roux-en-Y gastric bypass. The aim of this study was to assess the effect of modifying the recommended standard weight loss diet after bariatric surgery and procedures on reducing chronic inflammation in overweight patients. In the study, bioactive anti-inflammatory dietary components were used supportively. Changes in the concentrations of lipid parameters, liver parameters, antioxidant enzymes, cytokines, and chemokines were demonstrated. The enrichment of the diet, after bariatric surgery, with the addition of n-3 EFAs(Essential Fatty Acids), bioflavonoids, vitamins, and synbiotics resulted in higher weight losses in the patients in the study with a simultaneous reduction in parameters indicating liver dysfunction.
Provided in the present invention is a pharmaceutical composition of a small molecular GLP-1R receptor agonist suitable for oral administration. More specifically, the present invention relates to a pharmaceutical composition containing (S)-2-(3S,8S)-3-(4-(3,4-dichlorobenzyloxy)phenyl-7-((S)-1-phenylpropyl)-2,3,6,7,8,9-hexahydro-[1,4]-dioxino[2,3-g]isoquinoline-8-formylamino)-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)propionic acid (?OAD2?) and a pharmaceutically acceptable salt thereof, and a preparation method therefor. The composition may contain a low level of one or more oxidative degradation substances or may contain a low level of reactive oxygen species. The pharmaceutical composition provided in the present invention has low content of oxidative degradation impurity B and a low total impurity content, so that the composition can be stably stored for 12 months or more under normal temperature and normal humidity. The present invention further relates to a method for treating type II diabetes and indications related to improper blood glucose control using such pharmaceutical compositions.
Selected patients will undergo 1 session of TMS treatment to include a non-TMS baseline task and a TMS testing task. The baseline and the testing task are the self-same task. The baseline test demonstrates patient comprehension of instructions, as well as a baseline of task performance for comparison analysis. The TMS test will include the self-same task that may be randomized in terms of order of stimulus presentation. Each component--the baseline and the TMS task--will have a duration of 10 minutes, for a total intervention time of 20 minutes.

Individual pulses (100% motor threshold intensity, continuous temperature of 24-C) will be delivered upon the presentation of the stimulus or the verbal command for the language tasks. For the motor area, intermittent pulses will be delivered during random finger-tapping. Two research coordinators will perform the intervention, with one coordinator presenting the stimulus/giving commands, and the other positioning the TMS coil and delivering the individual pulse or pulse trains. For the language tasks, both research coordinators need to be well-harmonized: as one coordinator presents the stimulus, the other must simultaneously administer the pulse. The stimulus presentation will last for a duration of 1 second, in conjunction with the time-course of the pulse's disruption. One or both research coordinators must track the successful or unsuccessful inhibition of task completion for each trial. For example, if the patient was able to correctly name all but one picture during TMS, then task inhibition occurred in 1 out of 20 trials, suggesting a failure in the neuronavigation of Broca's area. The number of trials may vary depending on task and region-of-interest; however the intervention is not to exceed a total of 20 minutes. Upon conclusion of the TMS session, the patient will discuss the outcome with the treating physician and follow-on procedures will be scheduled. Patients will not need to undergo a post-treatment MRI, as the MRI scans are functioning as a technique for neuronavigation for precise targeting.

The safety of this protocol will be closely monitored and data will be used to determine whether any significant safety issues exist when using TMS therapy. Adverse events will be noted whenever they occur but will be recorded at the time of the TMS procedure.

All patients will have a thorough discussion to obtain informed consent. Additional meetings with the physicians will further clarify the nature of the study, reasons for transcranial magnetic stimulation, and the possible risks involved. The nature of this study does not require randomization, but rather attempts to isolate adverse and advantageous events should they occur.
The fixed-freeze-cycle protocol utilizing the AFA-Pro comprises a fixed freeze-cycle duration of 180 seconds. If PVI is not achieved with the first freeze-cycle, another 180 seconds freeze-cycle will be applied until documented PVI. After PVI no bonus freeze-cycle is applied.
The present invention relates to a natural composition effective in the treatment of bone fracture, and more specifically, to a natural composition effective in the treatment of skull fracture, comprising ginseng, Atractylodes japonica roots, Wolfiporia extensa, and liquorice. To address the above described problem and demand, the present invention provides a GamiSibjeondaebo composition effective in the treatment of skull fracture, which is extracted from a mixture of ginseng, Atractylodes japonica roots, Wolfiporia extensa, liquorice, steamed and dried Rehmannia glutinosa, Paeoniae Radix, Cnidium Officinale Makino, Angelica gigas, Astragalus membranaceus, Cinnamomum cassia Presl barks, natural pyrite, dried Albizzia julibrissin Durazz. barks, and Drynaria fortunei Smith rhizome. Specifically, the GamiSibjeondaebo composition comprises, with respect to 100 parts by weight of ginseng: 80-120 parts by weight of Atractylodes japonica roots; 80-120 parts by weight of Wolfiporia extensa; 80-120 parts by weight of liquorice; 80-120 parts by weight of steamed and dried Rehmannia glutinosa; 80-120 parts by weight of Paeoniae Radix; 80-120 parts by weight of Cnidium Officinale Makino; 80-120 parts by weight of Angelica gigas; 80-120 parts by weight of Astragalus membranaceus; 80-120 parts by weight of Cinnamomum cassia Presl barks; 120-180 parts by weight of natural pyrite; 120-180 parts by weight of dried Albizzia julibrissin Durazz. barks; and 120-180 parts by weight of Drynaria fortunei Smith rhizome. Additionally, the present invention provides a pharmaceutical composition comprising the GamiSibjeondaebo composition effective in the treatment of skull fracture.
Polycystic ovarian syndrome (PCOS) is one of the most common endocrinopathies among reproductive women worldwide, contributing greatly on the incidence of female infertility and gynecological cancers. It is a complex health condition combining of multiple symptoms like androgen excess, uncontrolled weight gain, alopecia, hirsutism, etc. Conventionally PCOS was associated with obesity while it is often found among lean women nowadays, making the disease more critical to diagnose as well treatment. The disorder has an impact on several signal transduction pathways, including steroidogenesis, steroid hormone activity, gonadotrophin regulation, insulin secretion, energy balance, and chronic inflammation. Understanding the aetiology and pathophysiology of PCOS is difficult due to its multiple causes, which include environmental factors, intricate genetic predisposition, and epigenetic modifications. Despite research supporting the role of familial aggregations in PCOS outcomes, the inheritance pattern remains unknown. Henceforth, to reduce the burden of PCOS, it is inevitably important to diagnose at early ages as well as intervene through personalized medicine. With this brief background, it was imperative to elucidate the genetic architecture of PCOS considering BMI as an controlling factor. This study aims to investigate the genetic basis behind obesity-mediated PCOS, focusing on both obese and lean individuals. It uses a comprehensive bioinformatics methodology to depict pathways and functionality enrichment, allowing for cost-effective risk prediction and management. In the present research, the representative study participants (N = 2) were chosen from a cross-sectional epidemiological survey, based on their anthropometric parameters and confirmation of PCOS. Upon voluntary participation and written consent, biological fluids (whole blood and buccal swab) were taken from where DNA was extracted. The clinical-exome sequencing was performed by the Next-generation Illumina platform using the Twist Human Comprehensive Exome Kit. A comprehensive bioinformatics methodology was employed to identify the most important, unique, and common genes. A total of 26,550 variants were identified in clinically important exomes from two samples, with 5170 common and 2232 and 2322 unique among PCOS lean and obese phenotypes, respectively. Only 262 and 94 variants were PCOS-specific in lean and obese PCOS. Three filters were applied to shortlist the most potent variants, with 4 unique variants in lean PCOS, 2 unique variants in obese PCOS, and 5 common variants in both. The study found that leptin signalling impairment and insulin resistance, as well as mutations in CYP1A1, CYP19A1, ESR1, AR, AMH, AdipoR1, NAMPT, NPY, PTEN, EGFR, and Akt, all play significant roles in PCOS in the studied group. Young women in West Bengal, India, are more likely to have co-occurring PCOS, which includes estrogen resistance, leptin receptor insufficiency, folate deficiency, T2DM, and acanthosis nigricans, with obesity being a common phenotypic expression.
Participants with UC who have never received therapy with platinum in the metastatic setting or for unresectable locally advanced disease will first receive cisplatin (either at 70 mg/m\^2 on Day 1 of a 21-day cycle or at a split dose of 35 mg/m\^2 on Days 1 and 8 of a 21-day cycle with a maximum body surface area of 2) and sacituzumab govitecan-hziy with maximum dose of 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle for up to 6 cycles. Based on DLTs observed, two additional lower doses may be tested to determine RP2D of sacituzumab govitecan-hziy in combination with cisplatin. If premature termination of 1 agent occurs due to toxicity, the other agent may be continued to complete up to 6 cycles of therapy. For participants who have not progressed, maintenance therapy will begin with infusions of avelumab 800 mg every 2 weeks beginning on Cycle 1, Day 1 and every 2 weeks thereafter and sacituzumab govitecan-hziy 10 mg/kg on Days 1 and 8 every 21 days.
Obesity is associated with an increased incidence of asthma. However, the mechanisms underlying this association are not fully understood. In this study, we investigated the role of thioredoxin-interacting protein (TXNIP) in obesity-induced asthma. Asthma was induced by intranasal injection of a protease from Aspergillus oryzae in normal diet (ND)- or high fat diet (HFD)-fed mice to investigate the symptoms. We measured TXNIP expression in the lungs of patients with asthma and in ND or HFD asthmatic mice. To explore the role of TXNIP in asthma pathogenesis, we induced asthma in the same manner in alveolar type 2 cell-specific TXNIP deficient (TXNIPCre) mice. In addition, the expression levels of pro-inflammatory cytokines were compared based on TXNIP gene expression in A549 cells stimulated with recombinant human tumor necrosis factor alpha. Compared to ND-fed mice, HFD-fed mice had elevated levels of free fatty acids and adipokines, resulting in high reactive oxygen species levels and more severe asthma symptoms. TXNIP expression was increased in both, asthmatic patients and HFD asthmatic mice. However, in experiments using TXNIPCre mice, despite being TXNIP deficient, TXNIPCre mice exhibited exacerbated asthma symptoms. Consistent with this, in vitro studies showed highest expression levels of pro-inflammatory cytokines in TXNIP-silenced cells. Overall, our findings suggest that increased TXNIP levels in obesity-induced asthma is compensatory to protect against inflammatory responses.
Background: T2DM has been considered as a chronic progressive incurable metabolic disease. Single-anastomosis gastric bypass (SAGB) was shown to be effective in obese patients in terms of weight reduction and T2DM remission, yet its effect on non-obese diabetics is not extensively studied. In this study, we tried to determine the anthropometric and glycemic outcomes of SAGB as a proposed line of treatment for type II diabetes mellitus (T2DM) patients with body mass index (BMI) 25-30 kg/m2.

Methods: From November 2013 to March 2016, a prospective study has been conducted at Ain-Shams University hospitals on 17 consecutive patients undergone SAGB. The demographic and anthropometric data of the patients, as well as their relevant laboratory results, were reported, other data including anti-diabetic medications, co-morbid metabolic diseases were also assessed. All patients were scheduled for laparoscopic SAGB and were advised to come in regular follow up at 1, 3, 6, 12 and 18 months postoperatively. T2DM Remission is considered if glycosylated hemoglobin (HbA1c) \<6.5 % and fasting plasma glucose (FPG) \< 126 mg/dl for at least 1 year without medication.
Placebo powder contains the same ingredients as the probiotic powder except the L. helveticus R0052 and B. longum R0175. All participants will consume the placebo for 28 days during one of two dosing phases.
Ultrasound guided sacroiliac joint injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml) per course. Single injection per course is being given.
Acupuncture Treatment Group: will get acupuncture treatment which will be applied to Baihui (DU20), Yintang (EX-HN3) points and bilateral Tai Chong (LR3), Hegu (LI4) points for 4 weeks, twice a week. They also will continue to receive the conventional rehabilitation programme.
PURPOSE:To enable immunological measurement of a trace amt. of hapten in a specimen in short time with high specificness and good reproducibility by inducing an agglutination reaction between the hapten and single kind of a monoclonal sensitized carrier deposited on single kind of monoclonal antibody sensitized carrier. CONSTITUTION:The reagent to be used for this immunochemical measurement consists of (A) a carboxyl group-contg. water-soluble monoolefin high polymer compd. bound chemically with hapten or the chemically modified matter thereof or a hapten-deposited carrier formed by binding chemically said compd. with a high polymer latex carrier having about 0.01-2mu grain size and (B) single kind of monoclonal antibody-deposited carrier for said hapten to be combined with the above-mentioned hapten-deposited carrier. A drop of a suitably diluted test specimen is placed on, for example, a clean slide plate and a drop of the above- mentioned monoclonal antibody-deposited carrier is dropped thereon then a drop of the hapten-deposited carrier is dropped thereon. The three are thereafter thoroughly mixed under oscillation for several minutes and the reaction for prohibiting the agglutination thereof is observed, by which a trace amt. of the hapten in the specimen is detected with good accuracy.